{"id":"yasmin-20","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-10","effect":"Breakthrough bleeding"},{"rate":"5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The ethinyl estradiol component suppresses the luteinizing hormone (LH) surge needed for ovulation, while drospirenone provides progestational activity and has antimineralocorticoid properties that may help reduce water retention and bloating. The combination also thickens cervical mucus and alters the endometrium to prevent fertilization and implantation.","oneSentence":"Yasmin 20 is an oral contraceptive that prevents ovulation through a combination of ethinyl estradiol and drospirenone, a progestin with antimineralocorticoid activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:30.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception"},{"name":"Acne vulgaris (in females seeking contraception)"},{"name":"Premenstrual dysphoric disorder (PMDD)"}]},"trialDetails":[{"nctId":"NCT07318337","phase":"NA","title":"Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS","status":"COMPLETED","sponsor":"Mst.Sumyara Khatun","startDate":"2024-07-01","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":60},{"nctId":"NCT06820307","phase":"PHASE1","title":"Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-02-25","conditions":"Pain","enrollment":50},{"nctId":"NCT03091595","phase":"PHASE2","title":"E4/DRSP Ovarian Function Inhibition Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2017-02-07","conditions":"Prevention of Pregnancy","enrollment":82},{"nctId":"NCT02710708","phase":"PHASE4","title":"YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-27","conditions":"Contraception","enrollment":1921},{"nctId":"NCT02841202","phase":"PHASE4","title":"The Effect of Oral Contraceptive Pills On Eyes","status":"COMPLETED","sponsor":"Kayseri Education and Research Hospital","startDate":"2014-01","conditions":"Adverse Effect of Oral Contraceptives, Subsequent Encounter","enrollment":40},{"nctId":"NCT03037944","phase":"EARLY_PHASE1","title":"Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2016-03-01","conditions":"Adenomyosis","enrollment":32},{"nctId":"NCT02488538","phase":"PHASE3","title":"Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-07","conditions":"Premenstrual Syndrome","enrollment":300},{"nctId":"NCT02562053","phase":"PHASE3","title":"Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome?","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-10","conditions":"Premenstrual Syndrome","enrollment":300},{"nctId":"NCT02681536","phase":"NA","title":"Miniflare Versus Long Protocol in Poor Responders","status":"UNKNOWN","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2016-02","conditions":"Infertility","enrollment":200},{"nctId":"NCT00818519","phase":"PHASE3","title":"GA YAZ ACNE in China Phase III","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":179},{"nctId":"NCT00624130","phase":"PHASE3","title":"Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Contraception","enrollment":453},{"nctId":"NCT00656981","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":541},{"nctId":"NCT00651469","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":534},{"nctId":"NCT02027337","phase":"PHASE4","title":"Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants","status":"UNKNOWN","sponsor":"Tyumen State Medical Academy","startDate":"2013-12","conditions":"Polycystic Ovarian Syndrome, Hyperandrogenism, Menstrual Irregularities","enrollment":200},{"nctId":"NCT00824187","phase":"PHASE3","title":"YAZ Premenstrual Dysphoric Disorder (PMDD) in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-01","conditions":"Premenstrual Dysphoric Disorder ( PMDD)","enrollment":187},{"nctId":"NCT01258660","phase":"PHASE1","title":"Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-12","conditions":"Contraception","enrollment":172},{"nctId":"NCT00819312","phase":"PHASE3","title":"YAZ, Oral Contraceptive Registration in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Contraception","enrollment":675},{"nctId":"NCT01590849","phase":"PHASE3","title":"Assessment of Autonomic Tone in Normotensive Women Using Combined Hormonal Oral Contraceptive Containing Drospirenone","status":"UNKNOWN","sponsor":"Instituto do Coracao","startDate":"2011-01","conditions":"Contraceptive Affecting the Autonomic Nervous System, Contraceptive Affecting Blood Pressure","enrollment":69},{"nctId":"NCT01482338","phase":"PHASE4","title":"Premenstrual Symptoms Treatment Comparing Between Oral Contraceptives Containing Desogestrel and Drospirenone","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2011-06","conditions":"Premenstrual Syndrome","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":295,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Yasmin 20","genericName":"Yasmin 20","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Yasmin 20 is an oral contraceptive that prevents ovulation through a combination of ethinyl estradiol and drospirenone, a progestin with antimineralocorticoid activity. Used for Contraception, Acne vulgaris (in females seeking contraception), Premenstrual dysphoric disorder (PMDD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}